The REMOVAL Trial Shows A Lower Risk Of Heart Disease With Metformin
A study at the University of Glasgow, Scotland, shows a cut in the long-term risk of heart disease with metformin (a drug used for the treatment of diabetes) in the middle-aged patients with type 1 diabetes (T1D) who are with increased risk factors related to cardiovascular diseases (CVD).
In the REMOVAL trial, researchers have used an ultrasound to measure atherosclerosis in the carotid arteries (in the neck area). Carotid arteries will supply blood to the neck, face and brain in the human body.
The total number of adult participants in the REMOVAL trial is 428, aged 40 years or more with a long-standing type 1 diabetes. The participants in the trial had at least three of the following risk factors related to cardiovascular diseases (CVD).
In the REMOVAL trial, the participants are under either metformin or matching placebo medication. Researchers observed the following in the participants taking metformin.
The researchers say that the REMOVAL trial shows a lower risk of heart disease with metformin in patients with type 1 diabetes (T1D). They also say that the guidelines should be updated as the study shows that use metformin can reduce blood sugar (glucose) levels within a very short time.
The chief investigator of the study was Professor John Petrie, MD, Ph.D., at the University of Glasgow, Scotland. The study was presented to the American Diabetes Association during 77th Scientific Sessions, San Diego Convention Center, the United States.
The study was published on June 11, 2017, in The Lancet Diabetes & Endocrinology. Title of the article was "Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomized, placebo-controlled trial".
Preeclampsia (Gestational Hypertension) Was Linked To The Increased Risk Of Heart Disease
The Heart Foundation, Australia says there is an enhanced risk of heart diseases in the future in those women who have suffered from preeclampsia or gestational hypertension (High blood pressure. Pregnancy-induced hypertension. PIH) during the pregnancy.
Ms. Julie Anne Mitchell, the national spokeswoman for the women's heart health of The Heart Foundation, Australia says those women who have suffered from preeclampsia or gestational hypertension (High blood pressure. Pregnancy-induced hypertension. PIH) during the pregnancy should monitor their heart health after the pregnancy. They call the pregnancy as an "ultimate cardiac stress test".
An Australian study on pregnant women shows the development of high blood pressure in about 30,000 women and preeclampsia in about 10,000 women. Preeclampsia is a dangerous complication and forces the heart to work harder. An earlier study shows the following complications in the future with preeclampsia (gestational hypertension).
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.